A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency
1 Division of Cancer Care and Epidemiology, Cancer Research Institute, 10 Stuart Street, 2nd Level, Queen's University, Kingston, ON K7L 3N6, Canada
2 Department of Community Health and Epidemiology, Carruthers Hall, Queen's University, Kingston, ON K7L 3N6, Canada
3 Kingston, Frontenac, Lennox and Addington (KFL&A) Public Health, 221 Portsmouth Avenue, Kingston, ON K7 M 1V5, Canada
4 Population Health Branch, Saskatchewan Ministry of Health, T.C. Douglas Building, 3475 Albert Street, Regina, SK S4 S 6X6, Canada
BMC Medicine 2010, 8:90 doi:10.1186/1741-7015-8-90Published: 22 December 2010
Selective serotonin reuptake inhibitors (SSRIs), a popular class of antidepressants, may increase breast cancer risk by stimulating the secretion of prolactin, a potential tumour promoter. We evaluated the effects of duration of SSRI use, cumulative dose, and latency on the risk of breast cancer by conducting a population-based case-control study utilizing Saskatchewan health databases.
Cases included 1,701 women with primary invasive breast cancer diagnosed from 2003 to 2006, and controls consisted of 17,017 women, randomly selected from the population registry. Use of SSRIs was compiled using the Saskatchewan prescription database. Unconditional logistic regression was conducted to evaluate the impact of duration of combined SSRI use (total number of prescriptions dispensed), cumulative dose (total dosage received) and timing of use (two or more years, two to seven years and more than seven years prior to index date) on the risk of breast cancer.
Overall, SSRI use was not associated with an increased risk of breast cancer regardless of our definition of cumulative use (total number of prescriptions dispensed and total dosage). In addition, our results indicate that prolonged SSRI use does not have a latent effect on breast cancer risk. Also, our findings are not suggestive of an increased risk of breast cancer with the use of individual SSRIs.
Our study improved upon most previous studies by having a longer follow-up period, a larger sample size of long-term SSRI users and consideration of risk during specific exposure time windows that take latency into account. Given the potential health benefits of using SSRIs, our results suggest that the issue of breast cancer risk may no longer be a concern for women requiring long-term SSRIs.